- The PI should contact the Insitutional Biosafety Committee Chair, Dr. David McCauley (405-325-9038, email@example.com), to discuss the planned activities prior to the final grant submission. This will enable a determination to be made in regards to any research involving recombinant or synthetic nucleic acid molecules or other proposed biohazardous work.
- After a preliminary determination that recombinant or synthetic nucleic acid molecule activities or potentially biological hazardous work are being planned, the PI should submit the following to IBC@ou.edu. This will initiate IBC review to verify that the proposed work is in compliance with all Federal, State and Local Guidelines and whether or not the activity falls within the category "exempt from the guidelines," while also assessing the necessary biosafety containment level:
- If it is determined that the proposed work is acceptable and "exempt from the guidelines," a letter confirming this will be forwarded to the PI to submit to the Office of Research Services.
- Should the proposed work fall into any existing NIH Recombinant or Synthetic Nucleic Acid category other than "exempt from the guidelines" (see a summary of the guidelines for clarification), the proposal will be discussed during the next meeting of the Institutional Biosafety Committee.
OU requires that every employee complete annual safety training for the types of work performed. Current Laboratory Safety (required for all laboratory personnel) and General Biosafety training is required for all personnel identified on any submitted IBC protocol. Bloodborne Pathogen training is additionally required for working with human cell lines. These training courses are found at on OnPoint at OnPoint.ou.edu. Training designation are housed in University PeopleSoft systems and can only be revised by departmental payroll coordinators or ePAF preparer.
Helpful Links to Regulatory Guidelines:
Conflict of Interest Policy